
|Articles|August 13, 2014
- Gastrointestinal Cancers (Issue 2)
- Volume 2
- Issue 1
The Importance of Testing for BRAF Status in CRC Patients
Author(s)Johanna Bendell, MD
Johanna Bendell, MD, director of GI Cancer Research Program, associate director, Drug Development Program, Sarah Cannon Research Institute, discusses the importance of testing CRC patients for BRAF status.
Johanna Bendell, MD, director of GI Cancer Research Program, associate director, Drug Development Program, Sarah Cannon Research Institute, discusses the importance of testing CRC patients for BRAF status.
View information about palliative resection in mCRC > >
Articles in this issue
over 11 years ago
An Analysis of Bevacizumab or Cetuximab for CRCover 11 years ago
Proactive Management of Regorafenib-Associated AEsover 11 years ago
Survival Benefit Confirmed With Palliative Resection in mCRC




































